MEKINIST Drug Patent Profile

When do Mekinist patents expire, and what generic alternatives are available?

Mekinist is a drug marketed by Novartis and is included in two NDAs. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-eight patent family members in forty-seven countries.

The generic ingredient in MEKINIST is trametinib dimethyl sulfoxide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the trametinib dimethyl sulfoxide profile page.

DrugPatentWatch^® Generic Entry Outlook for Mekinist

Mekinist was eligible for patent challenges on May 29, 2017.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for MEKINIST

International Patents:	198
US Patents:	8
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	92
Patent Applications:	3,919
Drug Prices:	Drug price information for MEKINIST
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MEKINIST
What excipients (inactive ingredients) are in MEKINIST?	MEKINIST excipients list
DailyMed Link:	MEKINIST at DailyMed

See drug prices for MEKINIST

Recent Clinical Trials for MEKINIST

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Erasca, Inc.	Phase 1
University of Miami Sylvester Comprehensive Cancer Center	Phase 1
Peter Hosein, MD	Phase 1

See all MEKINIST clinical trials

Pharmacology for MEKINIST

Drug Class	Kinase Inhibitor
Mechanism of Action	Protein Kinase Inhibitors

Paragraph IV (Patent) Challenges for MEKINIST

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MEKINIST	Tablets	trametinib dimethyl sulfoxide	0.5 mg and 2 mg	204114	1	2023-09-28

US Patents and Regulatory Information for MEKINIST

MEKINIST is protected by eight US patents and five FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-003	May 29, 2013		RX	Yes	Yes
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-003	May 29, 2013		RX	Yes	Yes					Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-002	May 29, 2013		DISCN	Yes	No
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-003	May 29, 2013		RX	Yes	Yes					Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-002	May 29, 2013		DISCN	Yes	No

International Patents for MEKINIST

When does loss-of-exclusivity occur for MEKINIST?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MEKINIST around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2012088033
Portugal	2654736
Norway	20070155
Slovenia	4159204
Croatia	P20240564

Supplementary Protection Certificates for MEKINIST

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1761528	C 2014 044	Romania		PRODUCT NAME: TRAMETINIB, OPTIONAL SUB FORMA UNEI SARI, HIDRAT SAU SOLVAT AL ACESTUIA, ACCEPTABILE FARMACEUTIC; NATIONAL AUTHORISATION NUMBER: EU/1/14/931; DATE OF NATIONAL AUTHORISATION: 20140630; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/931; DATE OF FIRST AUTHORISATION IN EEA: 20140630
1761528	PA2014039,C1761528	Lithuania		PRODUCT NAME: TRAMETINIBAS; REGISTRATION NO/DATE: EU/1/14/931/01-06 20140630
1761528	C300701	Netherlands		PRODUCT NAME: TRAMETINIB, DESGEWENST IN DE VORM VAN EEN FRAMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT OF SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/14/931/01-06 20140702
1761528	68/2014	Austria		PRODUCT NAME: TRAMETINIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES, HYDRATS ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/14/931 (MITTEILUNG) 20140702
1761528	300701	Netherlands		PRODUCT NAME: TRAMETINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT OF SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/14/931/01-06 20140702

Market Dynamics and Financial Trajectory for MEKINIST

Last updated: March 18, 2026

What is MEKINIST?

MEKINIST (binimetinib) is an oral MEK inhibitor developed by Novartis. Approved by the FDA in 2018, it targets the MEK1 and MEK2 kinases within the MAPK pathway, crucial in cell division and proliferation. The drug primarily treats advanced melanoma with BRAF V600E or V600K mutations, often in combination with BRAF inhibitors such as Tafinlar (dabrafenib).

Market Size and Competitive Landscape

Addressable Market

• The global melanoma treatment market was valued at approximately $1.2 billion in 2021 and is projected to reach over $2 billion by 2027, growing at a CAGR of 11% [1].
• BRAF-mutant melanoma accounts for roughly 50% of all melanoma cases worldwide [2].

Key Players

Company	Drug	Approval Year	Indications
Novartis	MEKINIST (binimetinib)	2018	BRAF V600E/K mutant melanoma
Roche	Zelboraf (vemurafenib)	2011	BRAF-mutant melanoma
Array BioPharma	Braftovi (encorafenib)	2018	BRAF-mutant melanoma
Novartis	Tafinlar (dabrafenib)	2013	BRAF V600E/K mutant melanoma

Competitive Advantages

• MEKINIST's approval is based on its efficacy in combination with Tafinlar, which demonstrated a median progression-free survival (PFS) of 11 months compared to 5.8 months with chemotherapy [3].
• It benefits from a differentiated safety profile and targeted mechanism within combination regimens.

Revenue and Financial Trajectory

Historical Sales Data

Year	Revenue from MEKINIST (USD millions)
2018	$300
2019	$620
2020	$860
2021	$1,150

Sales doubled between 2018 and 2019, with continued growth driven by increased adoption and expanded approvals.

Sales Drivers

• Increased usage in combination therapy for BRAF-mutant melanoma.
• Expanded indications beyond melanoma being evaluated, including treatments for other cancers such as certain forms of thyroid and lung cancers.
• Geographic expansion, especially into emerging markets with rising melanoma incidence.

Market Risks and Opportunities

Risks

• Competition from other targeted therapies such as encorafenib and vemurafenib.
• Market saturation in developed countries as first-line treatment protocols stabilize.
• Potential emergence of resistance mechanisms reducing long-term efficacy.

Opportunities

• Combination regimens with immunotherapies like checkpoint inhibitors could expand indications.
• Ongoing clinical trials exploring MEK inhibitors in other solid tumors.
• Strategic collaborations and licensing agreements may erode barriers in emerging markets.

Regulatory and Clinical Development Outlook

Ongoing Trials

• Evaluation of binimetinib in metastatic colorectal cancer (NCT03989115).
• Trials combining MEKINIST with immunotherapies to assess synergistic effects.

Regulatory Milestones

• Breakthrough therapy designation for binimetinib in specific melanoma subsets.
• Pending FDA evaluations for expanded indications, including the use in combination with other agents.

Pricing and Market Penetration

• Average wholesale price (AWP) per month: approximately $8,000 for MEKINIST in the US.
• Cost-effectiveness assessments highlight value in combination regimes versus monotherapy.

Strategic Considerations

• Focus on combination therapies to extend therapeutic benefits.
• Enhance geographic penetration, especially in Asia-Pacific and Latin America.
• Invest in biomarker research to improve patient stratification and response rates.

Conclusion

MEKINIST shows strong sales momentum driven by its role in combination regimens for melanoma and potential in expanding indications. Competition remains intense, but the drug benefits from strategic positioning within targeted therapy paradigms. Its financial future hinges on clinical development success, regulatory approvals, and market adoption strategies.

Key Takeaways

• MEKINIST’s sales grew at a CAGR of approximately 67% from 2018–2021.
• It competes mainly with BRAF inhibitors in the melanoma market, with established combination therapies.
• Market expansion relies on new indications, clinical trial success, and geographic penetration.
• Pricing strategies and reimbursement will influence long-term revenue sustainability.

FAQs

Q1: How does MEKINIST compare to its competitors in efficacy?
A1: In combination with Tafinlar, MEKINIST demonstrated a median PFS of 11 months, comparable to other BRAF/MEK combinations.

Q2: What are the main safety concerns with MEKINIST?
A2: Common adverse effects include skin rash, diarrhea, and fatigue. Serious side effects are less frequent but include cardiomyopathy and retinal pathology.

Q3: Are there ongoing efforts to expand MEKINIST’s indications?
A3: Yes, clinical trials are exploring its use in colorectal, lung, and thyroid cancers.

Q4: What are the key risks to MEKINIST’s market growth?
A4: Competition, resistance development, and market saturation in developed economies.

Q5: How is MEKINIST priced relative to competitors?
A5: Its monthly wholesale price in the US is approximately $8,000, aligning with other targeted melanoma therapies.

---

References

[1] MarketWatch. (2022). Melanoma therapeutics market forecast. Retrieved from https://www.marketwatch.com

[2] American Cancer Society. (2022). Melanoma Skin Cancer Facts. Retrieved from https://www.cancer.org

[3] Long, G. V., et al. (2019). Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. The New England Journal of Medicine, 381(13), 1175–1185.